Microenvironment-Mediated Resistance to Anti-Androgen Therapy

Jacob J. Orme; Haojie Huang

doi:10.1016/j.ccell.2020.07.007

Microenvironment-Mediated Resistance to Anti-Androgen Therapy

Jacob J. Orme, Haojie Huang

Biochemistry and Molecular Biology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In this issue of Cancer Cell, Zhang et al. expose new possibilities for targeting castration-resistant prostate cancer (CRPC). Activation of the HER2/HER3 axis by cancer-associated fibroblast-secreted NRG1 mediates castration resistance, recommending novel applications of clinical anti-NRG1/HER3 therapeutics in treating CRPC.

Original language	English (US)
Pages (from-to)	155-157
Number of pages	3
Journal	Cancer cell
Volume	38
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2020.07.007
State	Published - Aug 10 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2020.07.007

Cite this

@article{1056688f36bb426d9fd7df9de2e60e80,

title = "Microenvironment-Mediated Resistance to Anti-Androgen Therapy",

abstract = "In this issue of Cancer Cell, Zhang et al. expose new possibilities for targeting castration-resistant prostate cancer (CRPC). Activation of the HER2/HER3 axis by cancer-associated fibroblast-secreted NRG1 mediates castration resistance, recommending novel applications of clinical anti-NRG1/HER3 therapeutics in treating CRPC.",

author = "Orme, {Jacob J.} and Haojie Huang",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = aug,

day = "10",

doi = "10.1016/j.ccell.2020.07.007",

language = "English (US)",

volume = "38",

pages = "155--157",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Microenvironment-Mediated Resistance to Anti-Androgen Therapy

AU - Orme, Jacob J.

AU - Huang, Haojie

PY - 2020/8/10

Y1 - 2020/8/10

N2 - In this issue of Cancer Cell, Zhang et al. expose new possibilities for targeting castration-resistant prostate cancer (CRPC). Activation of the HER2/HER3 axis by cancer-associated fibroblast-secreted NRG1 mediates castration resistance, recommending novel applications of clinical anti-NRG1/HER3 therapeutics in treating CRPC.

AB - In this issue of Cancer Cell, Zhang et al. expose new possibilities for targeting castration-resistant prostate cancer (CRPC). Activation of the HER2/HER3 axis by cancer-associated fibroblast-secreted NRG1 mediates castration resistance, recommending novel applications of clinical anti-NRG1/HER3 therapeutics in treating CRPC.

UR - http://www.scopus.com/inward/record.url?scp=85088979057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088979057&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.07.007

DO - 10.1016/j.ccell.2020.07.007

M3 - Comment/debate

C2 - 32781041

AN - SCOPUS:85088979057

SN - 1535-6108

VL - 38

SP - 155

EP - 157

JO - Cancer cell

JF - Cancer cell

IS - 2

ER -

Microenvironment-Mediated Resistance to Anti-Androgen Therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this